Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global Peripheral Artery Angioplasty market was valued at USD 4.64 billion in 2024 and is projected to reach USD 10.22 billion by 2031, exhibiting a CAGR of 12.2% during the forecast period.
Peripheral artery angioplasty is a minimally invasive procedure used to treat peripheral arterial disease (PAD) by opening blocked arteries, primarily in the legs. The procedure involves inserting a balloon-tipped catheter into the narrowed artery and inflating it to compress plaque against the artery wall. This restores blood flow and is often accompanied by stent placement to maintain patency. The market growth is driven by the rising global prevalence of atherosclerosis, diabetes, and hypertension, all major risk factors for PAD. Additionally, technological advancements in drug-eluting stents and bioresorbable scaffolds are creating new growth opportunities.
The market is experiencing rapid growth due to several factors, including the aging global population, increasing adoption of sedentary lifestyles, and rising rates of obesity. Furthermore, the growing demand for minimally invasive procedures over traditional surgical options is a significant driver. The Asia-Pacific region shows particularly high growth potential due to improving healthcare infrastructure and increasing medical tourism. However, reimbursement challenges in emerging markets and the high cost of advanced stents remain restraining factors. Leading companies like Medtronic, Boston Scientific, and Abbott Laboratories continue to invest in R&D for next-generation devices with enhanced drug delivery capabilities and improved biocompatibility.
Rising Prevalence of Peripheral Artery Disease
The increasing global incidence of peripheral artery disease (PAD), particularly among aging populations and those with diabetes, is creating sustained demand for angioplasty procedures. Over 200 million people worldwide suffer from PAD, with rates increasing approximately 25% over the past decade.
Advancements in Minimally Invasive Technologies
Innovations in catheter-based systems, drug-eluting stents, and atherectomy devices are enabling more effective and less invasive treatments. Drug-eluting stents now demonstrate 85% reduced restenosis rates compared to bare-metal alternatives.
The global shift toward value-based healthcare is accelerating adoption of cost-effective interventional procedures over traditional surgical options
Healthcare systems are increasingly prioritizing minimally invasive techniques that reduce hospital stays and overall treatment costs. Peripheral angioplasty procedures average $15,000-$25,000 compared to $50,000+ for surgical bypass, creating significant system-wide savings.
MARKET CHALLENGES
High Procedure Costs and Reimbursement Limitations
Advanced angioplasty procedures and specialized stents face reimbursement challenges in many healthcare systems. Medicare and private insurers are implementing stricter reimbursement criteria for certain advanced interventional devices, particularly in emerging markets where healthcare infrastructure is still developing.
Other Challenges
Technical Complexity and Training Requirements
Peripheral artery angioplasty requires specialized interventional radiologists and cardiologists with specific training. The steep learning curve and need for continuous skill updates present challenges in scaling the procedure availability, particularly in regions with limited access to specialized medical centers.
Economic Constraints in Emerging Markets
Despite growing demand, many developing nations lack the healthcare infrastructure and funding to support widespread adoption of advanced angioplasty procedures. The average cost of a single drug-eluting stent alone exceeds the annual healthcare budget allocation per capita in several emerging economies.
Untapped Emerging Markets
Countries across Asia, Latin America, and Africa present significant growth opportunities as healthcare infrastructure improves and disposable income increases. India's interventional cardiology market is projected to grow at 15.4% CAGR through 2028, while Brazil and Mexico show similar potential for expansion of peripheral artery disease treatments.
Integration of Artificial Intelligence and Robotics
AI-powered imaging systems and robotic-assisted angioplasty platforms are creating new paradigms in precision medicine. Recent studies show AI-guided procedures reduce procedure time by 35% and improve outcomes by detecting subtle patterns invisible to human operators. The global AI in interventional cardiology market is projected to reach $2.1 billion by 2028.
Expansion of Outpatient and Ambulatory Centers
Advancements in catheter technology and hemostasis devices are enabling transition of peripheral angioplasty from inpatient to outpatient settings. Same-day discharge rates have increased from 15% to 65% over the past five years, significantly reducing healthcare costs and increasing patient access to interventional treatments.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Drug-Eluting Stents represent the most advanced segment due to their dual mechanism of mechanical support and controlled drug delivery, which significantly reduces restenosis rates compared to other technologies. Their adoption is driven by superior long-term patency rates and reduced need for repeat interventions. |
| By Application |
|
Hospitals constitute the dominant application segment due to their comprehensive infrastructure for complex vascular procedures, 24/7 emergency capabilities for critical limb ischemia cases, and multidisciplinary teams that manage both the interventional procedure and post-operative care continuum. |
| By End User |
|
Interventional Cardiologists represent the largest end-user segment due to their specialized training in catheter-based interventions, central role in catheterization labs, and primary responsibility for managing atherosclerotic vascular diseases across coronary and peripheral vascular territories. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Medtronic holds a significant market share in the peripheral artery angioplasty market, leveraging its extensive portfolio of stents, balloon catheters, and atherectomy devices. The market is characterized by intense competition among established medical device giants, with Abbott Laboratories and Boston Scientific capturing substantial market shares through their innovative drug-eluting stents and advanced balloon technologies.
Beyond the top three, other significant players are making substantial contributions to the competitive landscape. Cook Medical has strengthened its position through its specialized peripheral stent systems, while Becton Dickinson focuses on drug-coated balloon technologies. Cordis Corporation (a Cardinal Health company) maintains a strong presence with its complete portfolio of peripheral intervention devices, and Terumo Corporation leverages its strong Asian market presence to expand its global footprint in this sector.
Growth initiatives are increasingly focused on technological innovation and strategic partnerships. Companies are investing heavily in R&D for next-generation bioresorbable stents and drug-eluting balloons that offer better long-term outcomes. Several players have entered into collaborations with research institutions to develop next-generation neurovascular and peripheral vascular devices, while others are expanding their manufacturing capabilities in emerging markets to capture cost advantages.
Market expansion strategies also include aggressive physician training programs and clinical trial investments to demonstrate superior clinical outcomes. Companies are increasingly offering comprehensive procedural support packages that include not just devices but also procedural planning software and postoperative monitoring systems, creating more integrated solutions for vascular centers.
List of Key Peripheral Artery Angioplasty Companies ProfiledMedtronic plc (Ireland)
Abbott Laboratories (United States)
Boston Scientific Corporation (United States)
Becton, Dickinson and Company (United States)
Cook Medical Inc. (United States)
Cordis Corporation (United States)
Terumo Corporation (Japan)
Healthcare providers are increasingly adopting catheter-based interventions for peripheral artery disease, with over 85% of procedures now performed through minimally invasive techniques. This shift is driven by shorter recovery times and reduced hospital stays compared to traditional surgical options.
Other TrendsDrug-Eluting Stents Gain Market Share
The global market for drug-eluting stents in peripheral interventions has grown by approximately 23% annually, reaching $2.3 billion. These devices offer improved patency rates and reduced restenosis compared to bare-metal alternatives, particularly in below-the-knee applications where vessel diameters are smaller.
With the population over 65 expected to double by 2050, age-related peripheral artery disease continues to drive procedure growth. Current estimates indicate 2.1 million annual procedures globally, with projections reaching 3.4 million by 2030. The 65+ demographic accounts for 72% of these interventions.
Outpatient Settings Expand
Ambulatory surgical centers now perform over 40% of peripheral angioplasties, compared to just 15% a decade ago. This shift reduces healthcare costs by approximately 60% per procedure while maintaining equivalent safety profiles to hospital-based interventions.
Asia-Pacific markets are experiencing 18% annual growth in peripheral interventions, driven by improving healthcare infrastructure and increasing physician training programs. India and China collectively added over 500 new catheterization labs in the past year alone, expanding access to approximately 280 million additional people.
Technology Integration Accelerates
Robotic-assisted angioplasty systems are now deployed in over 200 centers worldwide, with studies showing 28% improvement in precision for complex lesion navigation. AI-powered planning tools now reduce procedure time by 19% while improving outcomes through personalized device selection algorithms.
Recent policy changes in major markets have created favorable reimbursement environments, with 34 U.S. states now covering peripheral angioplasty as a stand-alone procedure without requiring concurrent bypass surgery. This has increased patient access by approximately 40% since implementation.
Regional Analysis: Peripheral Artery Angioplasty MarketEurope
Europe maintains strong position in peripheral artery angioplasty innovation, with Germany and the UK leading in clinical research output and France demonstrating excellent outcomes in complex lesion treatment. Northern European countries show higher adoption rates of drug-coated balloons compared to southern regions. The EU regulatory environment facilitates efficient approval pathways while maintaining rigorous safety standards. Cross-border collaboration enables sharing of best practices among vascular specialists. Eastern European countries show the fastest growth rate as they catch up to Western European procedure volumes through infrastructure development and specialist training programs.
Asia-Pacific
Asia-Pacific demonstrates the world's highest growth rate in peripheral artery interventions, driven primarily by India's rapidly expanding interventional cardiology programs and China's massive patient population gaining access to advanced interventions. Australia and Japan maintain world-class outcomes with high adoption of the latest generation devices. South Korea leads in technology adoption per capita. Southeast Asian countries show rapid growth with international partnerships establishing advanced catheterization laboratories. The region benefits from both domestic production and international supply of devices and materials.
Latin America
Latin American markets show increasing collaboration between countries, with Brazil and Argentina leading in specialist training programs. Colombia and Chile demonstrate particularly strong growth in rural area outreach programs. Mexico benefits from proximity to the United States for both technology transfer and specialist training. Central American countries show emerging collaboration through regional medical associations that facilitate knowledge sharing and equipment standardization. Local manufacturing of some devices and supplies helps reduce costs while maintaining international quality standards.
Middle East & Africa
Middle Eastern markets show strong government support for developing specialized cardiology and interventional radiology units, with Gulf countries leading in infrastructure investment. African markets show the greatest potential for growth, though from a smaller current base. International partnerships help establish new catheterization laboratories with gradual technology transfer and local staff training. Regional medical associations play key roles in standardizing protocols and creating specialist networks. Both regions show increasing collaboration with global health organizations to expand access to life-saving interventions.
This report provides a comprehensive overview of the global Peripheral Artery Angioplasty market from 2020 to 2031, with detailed analysis of market size, growth trends, and industry dynamics. The data is compiled from industry reports, company financial statements, and market research databases, ensuring accuracy and reliability for strategic decision-making.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type (balloons, stents, catheters)
By application (coronary, peripheral, neurovascular)
By end-user (hospitals, ASCs, cath labs)
By technology (drug-eluting, bare metal, bioresorbable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level analysis for key markets
Competitive Landscape
Market share analysis of key players
Product portfolio and pricing strategies
Mergers, acquisitions, and partnerships
Market Dynamics
Drivers (aging population, rising CVD prevalence)
Restraints (stringent regulations, reimbursement policies)
Opportunities (emerging markets, technological innovation)
-> The global Peripheral Artery Angioplasty market was valued at USD 4.64 billion in 2024 and is projected to reach USD 10.22 billion by 2031.
-> Asia-Pacific shows the highest growth rate due to improving healthcare infrastructure, while North America maintains the largest market share due to advanced healthcare systems and high procedure volumes.
-> Key growth drivers include the aging global population, rising prevalence of peripheral artery disease, technological advancements in minimally invasive procedures, and increasing healthcare expenditure in emerging economies.
-> Leading companies include Medtronic, Boston Scientific, Abbott Laboratories, Cardinal Health, B. Braun, and Terumo Corporation, among others. These companies compete through product innovation, strategic partnerships, and geographic expansion.
-> The pandemic initially caused procedural delays due to hospital resource reallocation, but also accelerated the adoption of minimally invasive techniques and remote monitoring solutions, creating long-term growth opportunities.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates